A multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of low-dose ondansetron for adjuncative therapy in adult patients with obsessive-compulsive disorder who have not adequately responded
|Effective start/end date||11/15/10 → 6/30/14|
- Transcept Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.